Polycystic ovary syndrome: A threat to appearance, menstruation, and fertility
Affecting 1 in 10 U.S. females, this distressing condition can be treated, though not cured. Your compassionate care and on-point teaching can make a…
Women’s Health
Risks pf BSGI and PEM studies
According to a study in Radiology, a single breast-specific gamma imaging (BSGI) or positron emission mammography (PEM) test is “associated with a fatal radiation-induced…
Avastin may lose metastatic breast cancer indication
An U.S. Food and Drug Administration (FDA)-advisory panel has voted to strip Avastin’s indication for metastatic breast cancer because the drug is not effective…
In some situations, axillary node removal doesn’t improve breast cancer survival
A study presented at the American Society of Clinical Oncology June meeting found that removing additional axillary lymph nodes to look for breast cancer…
FDA approves new drug for osteoporosis
On June 1, the U.S. Food and Drug Administration (FDA) approved Prolia (denosumab), an injectable treatment for postmenopausal women with osteoporosis who are at…
Birth control pill most popular form of contraception in U.S.
Results from in-person interviews of women found that during 2006-2008 the most popular form of contraception in the U.S. was the oral contraception pill,…
Intraperitoneal chemotherapy: Improving the odds for ovarian cancer patients
Patients with ovarian cancer may receive intraperitoneal (IP) chemotherapy, which delivers chemotherapeutic agents directly into the peritoneal cavity. Drugs given by this route include…
March of Dimes releases new nursing education modules
The March of Dimes has released three new nursing education modules: Diabetes in Pregnancy, 4th Edition; Genetic Issues for Perinatal Nurses, 3rd Edition; and…
Drug approval for breast cancer
The U.S. Food and Drug Administration has approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer…
HAART and its effects on the heart
Many patients with HIV/AIDS are doing well on highly active antiretroviral therapy (HAART). Yet HAART can increase cardiovascular risks by reducing high-density lipoprotein levels,…
Drugs Today – July/August 2009
A weekly update of drug news, including alerts, approvals, and removals.
Polycystic ovary syndrome: A threat to appearance, menstruation, and fertility
Affecting 1 in 10 U.S. females, this distressing condition can be treated, though not cured. Your compassionate care and on-point teaching can…
Risks pf BSGI and PEM studies
According to a study in Radiology, a single breast-specific gamma imaging (BSGI) or positron emission mammography (PEM) test is “associated with a…
Avastin may lose metastatic breast cancer indication
An U.S. Food and Drug Administration (FDA)-advisory panel has voted to strip Avastin’s indication for metastatic breast cancer because the drug is…
In some situations, axillary node removal doesn’t improve breast cancer survival
A study presented at the American Society of Clinical Oncology June meeting found that removing additional axillary lymph nodes to look for…
FDA approves new drug for osteoporosis
On June 1, the U.S. Food and Drug Administration (FDA) approved Prolia (denosumab), an injectable treatment for postmenopausal women with osteoporosis who…
Birth control pill most popular form of contraception in U.S.
Results from in-person interviews of women found that during 2006-2008 the most popular form of contraception in the U.S. was the oral…
Intraperitoneal chemotherapy: Improving the odds for ovarian cancer patients
Patients with ovarian cancer may receive intraperitoneal (IP) chemotherapy, which delivers chemotherapeutic agents directly into the peritoneal cavity. Drugs given by this…
March of Dimes releases new nursing education modules
The March of Dimes has released three new nursing education modules: Diabetes in Pregnancy, 4th Edition; Genetic Issues for Perinatal Nurses, 3rd…
Drug approval for breast cancer
The U.S. Food and Drug Administration has approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced…
HAART and its effects on the heart
Many patients with HIV/AIDS are doing well on highly active antiretroviral therapy (HAART). Yet HAART can increase cardiovascular risks by reducing high-density…
Drugs Today – July/August 2009
A weekly update of drug news, including alerts, approvals, and removals.
Poll
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.